WHO ICTRP trial
High-dose I-131-MIBG therapy for high-risk neuroblastoma preceding myeloablative…
JPRN-jRCTs041180030 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs041180030 |
|---|---|
| Public title | High-dose I-131-MIBG therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation |
| Scientific title | Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation - High-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma |
| Primary sponsor | Wakabayashi Hiroshi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Conditions | Neuroblastoma High-risk neuroblastoma, 131I-MIBG therapy;D009447;High-risk neuroblastoma, 131I-MIBG therapy |
| Interventions | All patients receive 131I-MIBG at 666 MBq/kg. Subsequently, patients receive high-dose chemotherapy and hematopoietic stem cell transplantation. The recommended regimen is MEC regimen consisting of melphalan, etoposide, and carboplatin, or… |
| Registration date | Jan 23, 2019 |
| Target size | 8 |
| Secondary IDs | UMIN000025045 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: